Αρχική World News EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab World News EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab Από Ogkologos - 10 Απριλίου, 2025 648 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR What Is Mindfulness and How Can It Help People With Cancer? 5 Ιουλίου, 2022 Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... 5 Ιουνίου, 2023 FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer 24 Αυγούστου, 2022 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic 17 Απριλίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Giving Myself the Most Time and Best Chance at Beating Cancer:... ESMO Advocates for Equal Access to Optimal Cancer Care for all... EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... Five Questions With…Jessica, Katie, and Melanie